8-K
filed May 26, 2023, 7:59 PM ET
ticker ATRC
CIK 0001323885
other material
confidence high
sentiment neutral
materiality 0.40
Shareholders approve 2023 equity plan and ESPP increase by 750K shares
AtriCure, Inc.
- 2023 Stock Incentive Plan approved with 38.1M for, 2.3M against, 28K abstain.
- ESPP amendment approved, increasing authorized shares by 750,000; votes 40.3M for.
- All eight director nominees elected with majority votes (e.g., Michael Carrel 38.7M for).
- Deloitte & Touche ratified as independent auditor for FY2023 (42.1M for).
- Say-on-pay advisory vote passed with 33.7M for, 6.6M against.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
AtriCure, Inc. shareholders approved Election of eight directors to serve one-year terms expiring at the 2024 Annual Meeting of Stockholders at the 2023-05-25 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-25
Exact text from the filing
The stockholders of the Company voted on five items at the Annual Meeting of Stockholders held on May 25, 2023: 1. The election of eight directors to serve one-year terms expiring at the 2024 Annual Meeting of Stockholders and until their successors have been duly elected and qualified; 2. A proposal to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023; 3. The approval of the AtriCure, Inc. 2023 Stock Incentive Plan; 4. The approval of an amendment to the AtriCure, Inc. 2018 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 750,000; and 5. An advisory vote on the compensation of the Company’s named executive officers as disclosed in the proxy statement.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
AtriCure, Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers as disclosed in the proxy statement at the 2023-05-25 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-05-25
Exact text from the filing
The advisory vote on the compensation of the Company’s named executive officers as disclosed in the proxy statement received the following votes: For: 33,710,016 Against: 6,620,611 Abstain: 63,645 Broker Non-Votes: 2,455,488
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
AtriCure, Inc. shareholders approved Ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-25 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-25
Exact text from the filing
The proposal to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 received the following votes: For: 42,108,324 Against: 711,131 Abstain: 30,305 Broker Non-Votes: 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
AtriCure, Inc. shareholders approved Approval of the AtriCure, Inc. 2023 Stock Incentive Plan at the 2023-05-25 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-05-25
Exact text from the filing
The approval of the AtriCure, Inc. 2023 Stock Incentive Plan received the following votes: For: 38,096,753 Against: 2,269,227 Abstain: 28,292 Broker Non-Votes: 2,455,488
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
AtriCure, Inc. shareholders approved Approval of an amendment to the AtriCure, Inc. 2018 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 750,000 at the 2023-05-25 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-05-25
Exact text from the filing
The approval of an amendment to the AtriCure, Inc. 2018 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 750,000 received the following votes: For: 40,320,811 Against: 48,473 Abstain: 24,988 Broker Non-Votes: 2,455,488
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.